GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today highlighted the growing strategic importance of scalable domestic vaccine manufacturing infrastructure and diversified vaccine supply capabilities amid escalating global infectious disease threats. Recent public health events, including the World Health Organization’s declaration of a Public Health Emergency of International Concern (PHEIC) related to the ongoing Ebola outbreak involving the Bundibugyo strain, continued international spread of Clade I mpox, and recent hantavirus-related concerns, underscore the dynamic nature of global biodefense and pandemic preparedness requirements.
“These developments reinforce the importance of scalable and flexible vaccine preparedness infrastructure,” said David A. Dodd, Chairman and Chief Executive Officer of GeoVax. “GeoVax’s primary strategic focus remains the advancement of GEO-MVA, our Modified Vaccinia Ankara (MVA) mpox and smallpox vaccine candidate, which we believe is well aligned with growing global emphasis on diversified vaccine supply, domestic manufacturing capability, and long-term biodefense preparedness.”
GeoVax is advancing GEO-MVA to support global orthopoxvirus preparedness efforts and help address the need for expanded and diversified vaccine supply infrastructure. The company recently announced positive Scientific Advice from the European Medicines Agency supporting a Phase 3 immunobridging pathway toward potential regulatory approval. This pivotal Phase 3 trial is scheduled to initiate in Q4 2026, with data results anticipated by mid-2027.
GeoVax believes recent infectious disease developments further reinforce the strategic importance of diversified vaccine supply infrastructure, scalable domestic manufacturing capabilities, rapid-response vaccine platform technologies, and long-term investment in biodefense preparedness. The company also noted that the broader applicability of the MVA platform has been demonstrated across multiple infectious disease settings, including prior preclinical Ebola/hemorrhagic fever virus vaccine studies in which GeoVax’s MVA-based Ebola-Zaire vaccine candidate demonstrated complete protection in non-human primate lethal-challenge studies following Ebola virus exposure.
“Recent events continue to demonstrate that preparedness infrastructure cannot remain reactive or narrowly focused on individual outbreak cycles,” continued Mr. Dodd. “We believe the advancement of scalable domestic MVA-based manufacturing capability represents an important strategic objective for strengthening future biodefense readiness.”
For leaders in business and technology, this announcement signals a growing market for domestic vaccine production capabilities and highlights the need for diversified supply chains to mitigate risks from global outbreaks. The emphasis on MVA-based platforms suggests potential investment opportunities in biodefense and pandemic preparedness technologies. GeoVax’s focus on a domestic manufacturing infrastructure could reduce reliance on foreign supply sources, impacting supply chain resilience and national security.
GeoVax’s priority program is GEO-MVA, a next-generation MVA-based vaccine candidate for mpox and smallpox. The company is also developing Gedeptin®, a gene-directed enzyme prodrug therapy for oncology, and GEO-CM04S1, a next-generation COVID-19 vaccine candidate. For more information, visit www.geovax.com.
